Saiid Zarrabian - La Jolla Independent Chairman of the Board

LJPC -- USA Stock  

Earnings Call  This Week

Mr. Saiid Zarrabian is Independent Chairman of the Board of La Jolla Pharmaceutical Co. Mr. Zarrabian has over 37 years of operational experience in the biotechnology, pharmaceutical, informatics, software and instrumentationhardware industries. From 2012 to 2013, he served as President of the Protein Production Division and Senior Vice President of Intrexon, Inc., a synthetic biology company that went public in August 2013. Previously, he served as President and Chief Executive Officer of Cyntellect, Inc., a stem cell processing and visualization instrumentation Company from 2010 to 2012. Prior to Cyntellect, Mr. Zarrabian served as President and Chief Operating Officer of Senomyx, Inc., a public biotechnology company focused on the discovery and commercialization of new flavor ingredients, as Chief Operating Officer of publicly held Pharmacopeia, Inc., a leading provider of combinatorial chemistry discovery services and compounds, and as President and Chief Operating Officer of Molecular Simulations, Inc., a company providing software, databases and custom services for the pharmaceutical and chemical industries. Mr. Zarrabian has also performed executive consulting services for a variety of small to midsized companies including BioBlocks, Inc., eMolecules, Inc., Invitrogen Corporationrationration and SciTegic, Inc., where he served as executive consultant and acting Chief Operating Officer until the company was acquired by Accelrys, Inc
Age: 61  Chairman Since 2014      
Zarrabian has previously served on the boards of Penwest Pharmaceuticals Co, a pharmaceutical company focused on treatments for chronic pain, which was acquired by Endo Pharmaceuticals, Inc., eMolecules, Inc., a privately held chemistry eCommerce portal, Exemplar Pharma, LLC, a drug delivery company, which was acquired by Allergan, Inc., and Ambit Biosciences Corporationrationrationration, which was acquired by Daiichi Sankyo Company, Ltd. The Board has determined that Mr. Zarrabian should serve on our Board based on his substantial experience with other biotechnology and pharmaceutical companies.

Saiid Zarrabian Latest Insider Activity

Management Efficiency

The company currently holds 154.89 M in liabilities with Debt to Equity (D/E) ratio of 7.16 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. La Jolla Pharmaceutical has Current Ratio of 5.9 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 13 records


David MaddenDicerna Pharmaceuticals
Vernon LoboEquillium
Paul ManningDova Pharmaceuticals
Ting ZhengGlobal Cord Blood Corporation
Thomas MeyerAuris Medical Holding Ltd
Steven GorlinNantKwest
Yuen KamGlobal Cord Blood Corporation
Patrick SoonShiongNantKwest
Arnold OronskyDynavax Technologies Corporatio
Marc TessierLavignecDenali Therapeutics
Daniel BradburyEquillium
Richard PilnikDiaMedica Therapeutics
James HealyAuris Medical Holding Ltd

Entity Summary

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company was founded in 1989 and is headquartered in San Diego, California. La Jolla operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 169 people.La Jolla Pharmaceutical Company (LJPC) is traded on BATS Exchange in USA. It is located in 4550 Towne Centre Court and employs 169 people. La Jolla is listed under Pharmaceutical Products category by Fama And French industry classification.

La Jolla Pharmaceutical Leadership Team

George Tidmarsh, President CEO, Secretary, Director
Saiid Zarrabian, Independent Chairman of the Board
James Rolke, VP of RandD
Chester Zygmont, Director of Finance
Craig Johnson, Independent Director
Jennifer Carver, Senior Vice President Operations
Robert Rosen, Director
Kevin Tang, Chairman of the Board
Lakhmir Chawla, Chief Medical Officer
Laura Douglass, Independent Director
Dennis Mulroy, CFO
Darryl Wellinghoff, Chief Commercial Officer

Stock Performance Indicators

Did you try this?

Run Efficient Frontier Now


Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.